JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB273721

Human HK2 (Hexokinase II) knockout HCT116 cell line

Be the first to review this product! Submit a review

|

(7 Publications)

HK2 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Western blot - Human HK2 (Hexokinase II) knockout HCT116 cell line (AB273721)
  • WB

Lab

Western blot - Human HK2 (Hexokinase II) knockout HCT116 cell line (AB273721)

Lanes 1 - 4 : Merged signal (red and green). Green - ab209847 observed at 105 kDa. Red - loading control ab8245 (Mouse anti-GAPDH antibody [6C5]) observed at 37kDa.

ab209847 was shown to react with Anti-Hexokinase II in wild-type HCT 116 cells in western blot with loss of signal observed in HK2 knockout cell line ab273721 (HK2 knockout cell lysate ab275250). Wild-type and HK2 knockout HCT 116 cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3% milk in TBS-T (0.1% Tween®) before incubation with ab209847 and ab8245 (Mouse anti-GAPDH antibody [6C5]) overnight at 4° at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-Hexokinase II antibody [EPR20839] (<a href='/en-us/products/primary-antibodies/hexokinase-ii-antibody-epr20839-ab209847'>ab209847</a>) at 1/1000 dilution

Lane 1:

Wild-type HCT116 cell lysate at 20 µg

Lane 2:

HK2 knockout HCT116 cell lysate at 20 µg

Lane 2:

Western blot - Human HK2 (Hexokinase II) knockout HCT116 cell line (ab273721)

Lane 3:

HeLa cell lysate at 20 µg

Lane 4:

SH-SY5Y cell lysate at 20 µg

Predicted band size: 102 kDa

Observed band size: 105 kDa

false

Sanger Sequencing - Human HK2 (Hexokinase II) knockout HCT116 cell line (AB273721)
  • Sanger seq

Unknown

Sanger Sequencing - Human HK2 (Hexokinase II) knockout HCT116 cell line (AB273721)

Allele-1 : 1 bp insertion in exon 2.

Key facts

Cell type

HCT116

Species or organism

Human

Tissue

Colon

Form

Liquid

form

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2

Antibiotic resistance

Puromycin 1µg/mL

Disease

Carcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab273721-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab273730 Human wild-type HCT116 cell line", "number":"AB273721-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab273721 Human HK2 (Hexokinase II) knockout HCT116 cell line", "number":"AB273721-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab273721-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab273721 Human HK2 (Hexokinase II) knockout HCT116 cell line", "number":"AB273721-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
HK2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

McCoY5a + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Publications (7)

Recent publications for all applications. Explore the full list and refine your search

Hematological oncology 42:e3316 PubMed39526588

2024

Isocitrate dehydrogenase 2 mutation promotes cytarabine resistance in acute myeloid leukemia by Warburg effect.

Applications

Unspecified application

Species

Unspecified reactive species

Jinrong Yang,Zixu Wang,Kun Wu,Bo Nie,Liyin Li,Jingyan Ruan,Qiang Zhou,Yun Zeng,Mingxia Shi

BMC cancer 24:611 PubMed38773399

2024

The selective sponging of miRNAs by OIP5-AS1 regulates metabolic reprogramming of pyruvate in adenoma-carcinoma transition of human colorectal cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Jing-Yu Wang,Xiao-Ping Zhang,Hong-Kun Zhou,Hong-Xin Cai,Jin-Biao Xu,Bao-Gang Xie,Jean-Paul Thiery,Wu Zhou

Open life sciences 18:20220697 PubMed37941780

2023

Knockdown of SETD5 inhibited glycolysis and tumor growth in gastric cancer cells by down-regulating Akt signaling pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Jing Shi,Litao Yu,Changhong Zhu,Haiyan Zhong

Evidence-based complementary and alternative medicine : eCAM 2022:4026688 PubMed36588592

2022

Caudatin Inhibits the Proliferation, Invasion, and Glycolysis of Osteosarcoma Cells via the Wnt/- Catenin Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Yan Zhang,Zhizhong Sheng,Chi Su,Yuli Xia,Xiangfan Chen,Xiaobo Huang,Honglin Li,Changsheng Ma,Ligang Wang

Histology and histopathology :18565 PubMed36519522

2022

Circ-CCS regulates oxaliplatin resistance via targeting miR-874-3p/HK2 axis in colorectal cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaofeng Qiu,Qihua Xu,Bingling Liao,Sheng Hu,Ying Zhou,Huijun Zhang

Journal of bone oncology 37:100455 PubMed36276300

2022

Silencing of circCYP51A1 represses cell progression and glycolysis by regulating miR-490-3p/KLF12 axis in osteosarcoma under hypoxia.

Applications

Unspecified application

Species

Unspecified reactive species

Jian Yang,Zhiwei Liu,Ben Liu,Lishan Sun

Bioengineered 13:13055-13069 PubMed35635053

2022

Circ_0008068 facilitates the oral squamous cell carcinoma development by microRNA-153-3p/acylgycerol kinase (AGK) axis.

Applications

Unspecified application

Species

Unspecified reactive species

Yuanyuan Long,Chenxing Li,Baoyu Zhu
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com